# Integrative analysis of anti-breast CancerPotential of metabolites from Pseudomonas frederiksbergensis isolated from Taoerqi

## TL;DR

This study explores anti-breast cancer metabolites from a bacterium found in a Tibetan medicinal plant, identifying key molecular targets and their potential therapeutic value.

## Contribution

The study identifies novel anti-tumor metabolites and their regulatory targets from Pseudomonas frederiksbergensis isolated from Taoerqi.

## Key findings

- Secondary metabolites from Pseudomonas frederiksbergensis show significant anti-tumor activity in breast cancer cells.
- Key regulatory targets like SARM1, RGS5, PROM2, and BAG1 were validated through qPCR and Western blotting.
- A clinical risk assessment model was developed to explore the prognostic value of these targets in breast cancer.

## Abstract

The Tibetan medicinal botanical drug Taoerqi has long been recognized for its anti-inflammatory, antibacterial, and tumor-inhibitory properties.

Botanical drug focuses on the isolation and characterization of secondary metabolites from Pseudomonas frederiksbergensis, an endophytic bacterium isolated from Taoerqi roots. The metabolites were obtained through fermentation and purification processes and were evaluated for their anti-breast cancer activities using cellular assays and transcriptomic analysis. Key regulatory targets, including SARM1, RGS5, PROM2, and BAG1, were identified through bioinformatics analysis and validated using qPCR and Western blotting. Furthermore, a clinical risk assessment model was constructed using breast cancer transcriptome databases to explore the potential prognostic value of these targets.

The secondary metabolites from Pseudomonas frederiksbergensis exhibit significant anti-tumor effects and highlight their potential molecular mechanisms in breast cancer regulation.

This study provides insights into the therapeutic potential of these metabolites and lays the groundwork for future preclinical and in vivo investigations.